Xolair (Omalizumab) Insurance Denial Appeal Guide

Xolair (omalizumab) is approved for moderate-to-severe allergic asthma, chronic idiopathic urticaria (hives), chronic rhinosinusitis with nasal polyps, and food allergies. Prior authorization and step therapy requirements are common barriers to access.

FDA-Approved Indications

  • Moderate-to-severe persistent allergic asthma (age 6+)
  • Chronic idiopathic urticaria (age 12+)
  • Chronic rhinosinusitis with nasal polyps (age 18+)
  • IgE-mediated food allergy (age 1+) — newly approved 2024

Common Denial Reasons

  • IgE levels outside insurer's range requirements
  • Step therapy not completed (inhaled corticosteroids, LABA, etc.)
  • Prior authorization documentation insufficient
  • Duration of therapy limits

Appeal Strategy

  1. Document IgE levels and allergen sensitization
  2. Show failure of standard controller therapies
  3. Allergist/pulmonologist letter of medical necessity
  4. ER visits and hospitalizations due to condition
  5. Quality of life documentation (ACT score, UAS7 for urticaria)
  6. Cite GINA guidelines for severe asthma

Detailed Guides

Appealing Xolair Food Allergy Coverage Denials

Appeal Xolair (omalizumab) food allergy insurance denials. New FDA indication, clinical trial evidence, and coverage arguments.

Need Help Writing Your Appeal?

Our AI-powered tool analyzes your denial letter and generates a personalized appeal in minutes. Upload your denial and get started for free.

Start Your Free Appeal

Frequently Asked Questions

What IgE level is needed for Xolair?

For allergic asthma, Xolair is indicated for patients with IgE levels between 30-1,500 IU/mL with a positive skin test or RAST to a perennial aeroallergen. The dose is determined by your IgE level and body weight.

Related Resources